Active Stocks: Enzon Pharmaceuticals Inc. (NASDAQ:ENZN), Atara Biotherapeutics, Inc. (NASDAQ:ATRA), Cascade Bancorp (NASDAQ:CACB), Regulus Therapeutics Inc. (NASDAQ:RGLS), Ceres, Inc. (NASDAQ:CERE)

Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) belongs to Healthcare sector. Its net profit margin is 100.00% and weekly performance is 19.01%. On last trading day company shares ended up $1.69. Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) distance from 50-day simple moving average (SMA50) is 30.46%. Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) announced a special cash dividend for its investors. The biotechnology company will pay the special dividend on August 12, 2015 to its shareholders of record on July 21, 2015.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares moved up 14.51% in last trading session and ended the day at $62.03. ATRA return on assets is -31.00%. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) quarterly performance is 29.55%. On 9 July, Atara Biotherapeutics, Inc. (NASDAQ:ATRA) announced the pricing of its underwritten public offering of 3,461,538 shares of its common stock at a public offering price of $52.00 per share. In addition, Atara Bio granted the underwriters a 30-day option to purchase up to an additional 519,230 shares of common stock at the public offering price. All of the shares in the offering will be sold by Atara Bio. The offering is expected to close on July 15, 2015, subject to customary closing conditions.

On 13 July, Cascade Bancorp (NASDAQ:CACB) shares moved up 0.57% and was closed at $5.30. CACB EPS growth in last 5 year was 14.90%. Cascade Bancorp (NASDAQ:CACB) year to date (YTD) performance is 2.12%. Cascade Bancorp (NASDAQ:CACB) was downgraded by Zacks from a “strong-buy” rating to a “hold” rating in a research note issued on Tuesday.

Regulus Therapeutics Inc. (NASDAQ:RGLS) ended the last trading day at $11.03. Company weekly volatility is calculated as 5.99% and price to cash ratio as 3.78. Regulus Therapeutics Inc. (NASDAQ:RGLS) showed a weekly performance of 6.88%. On 7 July, Regulus Therapeutics Inc. (NASDAQ:RGLS) has strengthened its senior management team with the appointment of two new partners.

Ceres, Inc. (NASDAQ:CERE) shares moved up 4.42% in last trading session and ended the day at $1.89. CERE Gross Margin is -94.70% and its return on assets is -97.10%. Ceres, Inc. (NASDAQ:CERE) quarterly performance is -7.35%.On 10 July, Ceres, Inc. (NASDAQ:CERE) announced financial results for the three months ended May 31, 2015 and provided an update on its business and product development pipeline. Total revenues increased by $0.3 million to $1.1 million for the quarter ended May 31, 2015 compared to the same period last year

Leave a Reply

Your email address will not be published. Required fields are marked *